June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Prevalence of ptosis after topical mitomycin C therapy for conjunctival neoplasia
Author Affiliations & Notes
  • Rosalind M K Stewart
    Department of Eye and Vision Science, University of Liverpool, Liverpool, United Kingdom
    St Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, United Kingdom
  • Nihal Kenawy
    Department of Eye and Vision Science, University of Liverpool, Liverpool, United Kingdom
    St Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, United Kingdom
  • Heinrich Heimann
    Department of Eye and Vision Science, University of Liverpool, Liverpool, United Kingdom
    St Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, United Kingdom
  • Bertil E Damato
    Ocular Oncology Service, University of California, San Francisco, CA
  • Footnotes
    Commercial Relationships Rosalind Stewart, None; Nihal Kenawy, None; Heinrich Heimann, None; Bertil Damato, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 1602. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Rosalind M K Stewart, Nihal Kenawy, Heinrich Heimann, Bertil E Damato; Prevalence of ptosis after topical mitomycin C therapy for conjunctival neoplasia. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):1602.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

Topical mitomycin C (MMC) is well established as a primary or adjunctive therapy for ocular surface neoplasia. Adverse effects include allergic reactions, epiphora secondary to punctual stenosis, and limbal stem cell deficiency. Ptosis is reported rarely (1%). We suspected that the true incidence was under-reported and therefore studied the prevalence of this complication in our patients who had received topical MMC therapy.

 
Methods
 

A retrospective clinical study was undertaken. All patients treated with topical MMC between September 2009 and November 2014 at the Liverpool Ocular Oncology Centre, UK, were identified from a clinical database. Patient demographics, diagnosis, treatment dates and dose/number of cycles of MMC therapy were recorded. Patients were contacted by telephone and asked if they had noted any difference to the eyelids following treatment and if they had undergone or been offered lid surgery. Statistical analysis was performed using the 1-way ANOVA test.

 
Results
 

Fifty-four patients were identified; with a mean age of 62 years (range, 27-90) at the time of treatment. Thirty-one were male and 25 female. Twenty-seven patients (50%) were treated for conjunctival melanoma, 22 (41%) for conjunctival melanocytic intraepithelial neoplasia, 4 (7%) for conjunctival squamous cell carcinoma, and 1 (2%) for conjunctival papilloma with severe dysplasia. MMC 0.02 or 0.04% was prescribed 2 weeks following tumour excision and complete healing of the conjunctiva, for weekly courses with 3 week rest periods, for 1-12 (mean,4.2) cycles.<br /> Three patients were known to be deceased. Of the remaining 51, 45 (88%) were contacted. Follow up was 1-63 (median 23) months post-treatment. Nineteen patients (42%) reported ptosis, with 7 (16%) having been offered ptosis surgery and a further 1 (2%) actually undergoing surgery. There was no correlation with patient age (p>0.1), number of cycles of MMC (p>0.3), or co-existence of other severe side effects (p>0.7).

 
Conclusions
 

Ptosis after topical MMC therapy at a standard dose and regime is vastly under-reported. Patients should be warned of this potential adverse event.

 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×